Clicky

Biogen Idec Inc.(BIIB)

Description: Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); TYSABRI to treat relapsing MS; RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin's lymphoma (NHL); FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. The company's products that completed Phase III clinical trials comprise TECFIDERA (BG-12) for MS; Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a; and long-lasting Factor VIII and IX product candidates for the treatment of hemophilia. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; and ANTI-TWAEK for lupus nephritis. The company's Phase I clinical trial products comprise Anti-LINGO for MS; BIIB037 for Alzheimer's disease; Neublastin for neuropathic pain; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial product includes ISIS-SMNRx for spinal muscular atrophy. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.


Keywords: Medicine Biotechnology S&P 500 Pain Immunology Nasdaq 100 Monoclonal Antibodies Alzheimer's Disease Lymphoma Monoclonal Antibody Psoriasis Multiple Sclerosis Disability Specialty Drugs Neurodegenerative Diseases Idiopathic Pulmonary Fibrosis Hemophilia Degenerative Disease Neuropathic Pain Pulmonary Fibrosis Immunosuppressants Lupus Chronic Lymphocytic Leukemia Plaque Psoriasis Autoimmune Disorders Interferon Progressive Immune Disorders Clinical Trial Product Lymphocytic Leukemia Treatment Of Hemophilia Spinal Muscular Atrophy Lupus Nephritis Treatment Of Neurodegenerative Diseases Cd20 Severe Plaque Psoriasis Nephritis Swedish Orphan Biovitrum Clinical Trial Products Acorda Therapeutics B Cell Non Hodgkin's Lymphoma Cd40 Optic Neuritis Portola Pharmaceuticals

Home Page: www.biogen.com

BIIB Technical Analysis

225 Binney Street
Cambridge, MA 02142
United States
Phone: 617 679 2000


Officers

Name Title
Mr. Michael R. McDonnell CPA Exec. VP & CFO
Ms. Susan H. Alexander Esq. Exec. VP, Chief Legal Officer & Sec.
Mr. Christopher A. Viehbacher Pres, CEO & Director
Ms. Robin C. Kramer Sr. VP & Chief Accounting Officer
Ms. Nicole Murphy Head of Pharmaceutical Operations & Technology
Mr. Michael Hencke Head of Investor Relations
Ms. Natacha Gassenbach Chief Communication Officer & Head of Corp. Affairs
Dr. Ginger Gregory Exec. VP & Chief HR Officer
Dr. Anabella Villalobos Ph.D. Head of Biotherapeutics & Medicinal Sciences
Dr. Sanjay Jariwala Sr. VP of Worldwide Medical

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 18.4502
Trailing PE: 14.2121
Price-to-Book MRQ: 3.2581
Price-to-Sales TTM: 3.9385
IPO Date: 1991-09-16
Fiscal Year End: December
Full Time Employees: 9610
Back to stocks